BCAB

BioAtla, Inc. (NASDAQ:BCAB) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in San Diego, California. The company went public in December 2020 and specializes in developing innovative cancer treatments using its proprietary <b>Conditionally Active Biologic (CAB)</b> platform technology. BioAtla focuses exclusively on creating targeted therapies for solid tumor cancers, with multiple drug candidates currently in various phases of clinical trials. The company has no approved products and generates minimal revenue, operating as a research and development-focused biotech enterprise seeking to advance its pipeline toward potential commercialization or strategic partnerships.